THE ROLE OF MITOCHONDRIAL MARKERS IN THE PATHOGENESIS OF PREECLAMPSIA AND THE EVALUATION OF THE EFFICIENCY OF RESPIRATORY THERAPY IN THE TREATMENT OF PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data available in the current literature on the markers of preeclampsia and oxidative stress, as well as the impact of therapeutic methods on the development of preeclampsia. Material and methods. The review included the data available in foreign and Russian articles published in the past 10 years and found in Pubmed on this topic. Results. The paper describes the current markers of preeclampsia, such as endoglin, placental growth factor, soluble fms-like tyrosine kinase 1, and others, as well as immunological activators that have a marked proinflammatory effect (mitochondrial damage-associated molecular patterns (DAMPs)). It shows new treatments for gestational hypertension and pre-eclampsia by respiratory therapy (continuous positive airway pressure (CPAP)). Conclusion. It is necessary to perform further investigations of the impact of mitochondrial DAMPs on the development of preeclampsia and to evaluate the efficiency of CPAP support in the treatment of preeclampsia.

Full Text

Restricted Access

About the authors

Tatyana Vyacheslavovna Skovorodina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: t_skovorodina@oparina4.ru
Ph.D. Moscow 117997, Ac. Oparina str. 4, Russia

Polina A. Vishnyakova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vpa2002@mail.ru
researcher at the Laboratory of mitochondrial medicine Moscow 117997, Ac. Oparina str. 4, Russia

Mikhail Yu. Vysokikh

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: m_vysokikh@oparina4.ru
PhD, Head of mitochondrial medicine research group Moscow 117997, Ac. Oparina str. 4, Russia

Roman G. Shmakov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: m_vysokikh@oparina4.ru
chief physician Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The „Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am. J. Obstet. Gynecol. 2011; 204(3): 193-204.
  2. Turpin C.A., Sakyi S.A., Owiredu W.K., Ephraim R.K., Anto E.O. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy Childbirth. 2015; 15: 189.
  3. Ходжаева З.С., Коган Е.А., Клименченко Н.И.,Акатьева А.С., Сафонова А.Д., Холин А.М., Вавина О.В., Сухих Г.Т. Клинико-патогенетические особенности ранней и поздней преэклампсии. Акушерство и гинекология. 2015; 1: 12-7.
  4. Grill S., Rusterholz C., Zanetti-Dällenbach R., Tercanli S., Holzgreve W., Hahn S., Lapaire O. Potential markers of preeclampsia-a review. Reprod. Biol. Endocrinol. 2009; 7: 70.
  5. De Vivo A., Baviera G., Giordano D., Todarello G., Corrado F., D’anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008; 87(8): 837-42.
  6. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006; 12(6): 642-9.
  7. Bilban M., Ghaffari-Tabrizi N., Hintermann E., Bauer S., Molzer S., Zoratti C. et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J. Cell Sci. 2004; 117(8): 1319-28.
  8. Воднева Д.Н., Дубова Е.А., Павлов К.А., Шмаков Р.Г., Щеголев А.И. Роль кисспептинов в развитии ранней и поздней преэклампсии. Акушерство и гинекология. 2014; 8: 65-70.
  9. McCarthy C.M., Kenny L.C. Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia? Am. J. Reprod. Immunol. 2016; 76(5): 341-7. doi: 10.1111/aji.12526.
  10. Wenceslau C.F., McCarthy C.G., Szasz T., Spitler K., Goulopoulou S., Webb R.C.; Working Group on DAMPs in Cardiovascular Disease. Mitochondrial damage-associated molecular patterns and vascular function. Eur. Heart J. 2014; 35(18): 1172-7.
  11. Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C. et al. Autophagy proteins regulateinnate immune responses by inhibiting the release of mitochondrialDNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011; 12(3): 222-30.
  12. He J., Lu Y., Xia H., Liang Y., Wang X., Bao W. et al. Circulating mitochondrial DAMPs are not effective inducers of proteinuria and kidney injury in Rodents. PLoS One. 2015; 10(4): e0124469.
  13. Yinon D., Lowenstein L., Suraya S., Beloosesky R., Zmora O., Malhotra A., Pillar G. Preeclampsia is associated with sleep disordered breathing and endothelial dysfunction. Eur. Respir. J. 2006; 27(2): 328-33.
  14. Kapsimalis F. Obstructive sleep apnea in pregnancy. Sleep Med. Clin. 2007; 2: 603-13.
  15. Coussons-Read M.E., Okun M.L., Nettles C.D. Psychosocial stress increases inflammatory markers and alters cytokine production across pregnancy. Brain Behav. Immun. 2007; 21(3): 343-50.
  16. Hopps E., Caimi G. Obstructive sleep apnea syndrome: links betwen pathophysiology and cardiovascular complications. Clin. Invest. Med. 2015; 38(6): E362-70.
  17. Whitehead C., Tong S., Wilson D., Howard M., Walker S.P. Treatment of early-onset preeclampsia with continuous positive airway pressure. Obstet. Gynecol. 2015; 125(5): 1106-9.
  18. Poyares D., Guilleminault C., Hachul H., Fujita L., Takaoka S., Tufik S., Sass N. Preeclampsia and nasal CPAP: Part 2. Hypertension during pregnancy, chronics noring, and early nasal CPAP intervention. Sleep Med. 2007; 9(1): 15-21.
  19. Blyton D.M., Skilton M.R., Edwards N., Hennessy A., Celermajer D.S., Sullivan C.E. Treatment of sleep disordered breathing reverses low fetal activity levels in preeclampsia. Sleep. 2013; 36(1): 15-21.
  20. Churchill D., Duley L., Thornton J.G., Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst. Rev. 2013; (7): CD003106. doi: 10.1002/14651858.CD003106. pub2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media